Decibel Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 51
Employees
  • Stock Symbol
  • DBTX
Stock Symbol
  • Share Price
  • $7.56
  • (As of Friday Closing)

Decibel Therapeutics General Information

Description

Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1325 Boylston Street
  • Suite 500
  • Boston, MA 02215
  • United States
+1 (617) 000-0000

Decibel Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Decibel Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.56 $7.51 $6.18 - $24.39 $188M 24.9M 40.9K $3.00

Decibel Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 32,276
Revenue 0 0 0 0
EBITDA (41,075) (37,750) (42,314) (36,385)
Net Income (42,516) (39,337) (42,672) (36,163)
Total Assets 196,895 67,285 42,835 93,288
Total Debt 201 193 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Decibel Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Decibel Therapeutics‘s full profile, request access.

Request a free trial

Decibel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Decibel Therapeutics‘s full profile, request access.

Request a free trial

Decibel Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformativ
Drug Discovery
Boston, MA
51 As of 2021
00000
0000 0000-00-00
00000000 00000

000000

piscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim ve
0000 000000000
Boston, MA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
0000 000000000
Lexington, MA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Decibel Therapeutics Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akouos Formerly VC-backed Boston, MA 00 00000 00000000 00000
000000000 00000000 Formerly VC-backed Lexington, MA 00 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Tübingen, Germany 000.00 00000000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Amsterdam, Netherlands 00.000 00000000000 00.000
You’re viewing 5 of 11 competitors. Get the full list »

Decibel Therapeutics Patents

Decibel Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10813947-B1 Methods of otoprotection against platinum-based antineoplastic agents Active 31-May-2019 000000000
US-20210038640-A1 Methods of otoprotection against platinum-based antineoplastic agents Pending 31-May-2019 000000000
EP-3863605-A1 Aav1 vectors and uses thereof for treatment of otic indications Pending 11-Oct-2018 000000000
CA-3115810-A1 Aav1 vectors and uses thereof for treatment of otic indications Pending 11-Oct-2018 000000000
AU-2019357048-A1 Aav1 vectors and uses thereof for treatment of otic indications Pending 11-Oct-2018 C12N15/86

Decibel Therapeutics Executive Team (19)

Name Title Board Seat Contact Info
Jens Eckstein Ph.D Board Member & Co-Founder
Elisabeth Leiderman MD Chief Financial Officer, Finance & Executive
Ronald Vigliotta Chief Accounting Officer, Accounting & Vice President
Cynthia Hu Chief Legal Officer & Corporate Secretary
John Lee Chief Scientific Officer & Executive Vice President
You’re viewing 5 of 19 executive team members. Get the full list »

Decibel Therapeutics Board Members (18)

Name Representing Role Since
Abbie Celniker Ph.D Third Rock Ventures Board Member 000 0000
Anthony Philippakis Ph.D GV Board Member 000 0000
Christine Poon Decibel Therapeutics Board Member 000 0000
Christine Poon Self Board Member 000 0000
Craig Muir Third Rock Ventures Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Decibel Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial